Scarica l'app Stockscreener
11.63
1.77%
-0.21
Pre-mercato:
11.54
-0.09
-0.77%
Compass Pathways Plc Adr Borsa (CMPS) Ultime notizie
CMPS: COMP360 shows durable efficacy in TRD, with launch and broad site readiness expected in the coming year - TradingView
CMPS: COMP360 targets TRD launch in H1 2027, leveraging strong data, payer support, and clinic readiness - tradingview.com
CMPS: Psychedelic therapy for TRD nears FDA approval, promising rapid, durable relief and broad adoption - tradingview.com
CMPS: COMP360's rapid, durable TRD results and robust launch prep signal a paradigm shift in psychiatry - tradingview.com
Fluence to develop psilocybin therapy training for Compass - investing.com
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training - Finviz
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 - FXEmpire
Compass Pathways stock hits 52-week high at 15.4 USD - investing.com
Compass Pathways stock shows durable results in depression trial - investing.com
IRWD Stock Price, Quote & News - Syfe
Compass Pathfinder Limited: Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year - FinanzNachrichten.de
AQST Stock Price, Quote & News - Syfe
Lyell Immunopharma, Inc. (LYEL) Stock Price & News - Syfe
CytomX Therapeutics, Inc. (CTMX) Stock Price & News - Syfe
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question - sahmcapital.com
Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS) - MarketBeat
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions - Sahm
COMPASS (CMPS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Latest Reading; Session Move: Shares Close 0.79% HigherEarnings Acceleration Picks - dars.gov.et
COMPASS (CMPS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Latest Reading - www.dars.gov.et
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionEarnings Call Transcript - careplusvn.com
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionAdjusted Earnings Analysis - dars.gov.et
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionMargin Compression Risk - dars.gov.et
COMPASS (CMPS) Technical Check: Climbs 1.31% to $13.90 for the Current Session; Level Position: the Near-Term Reference Band Stretches From $13.21 to $14.60 in the Current UpdateChart Pattern Alerts - careplusvn.com
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances - Yahoo Finance
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CMPS: COMP360 targets a 2027 launch, offering rapid, durable relief for TRD and advancing a PTSD program - TradingView
HC Wainwright Cuts Earnings Estimates for Compass Pathways - MarketBeat
COMPASS Pathways (CMPS) insider files Form 144 for 26,000 ADS sale - stocktitan.net
COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run - Sahm
COMPASS Pathways plc (5Y6.F) stock price, news, quote and history - Yahoo Finance Singapore
Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Compass Pathways partners with VA on psilocybin trial for veterans - Investing.com
Compass Pathfinder Limited: Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin - FinanzNachrichten.de
Compass Pathways (NASDAQ:CMPS) Trading 9.8% HigherWhat's Next? - MarketBeat
Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips - Investing.com
COMPASS Pathways Reports Q2 2026 Financials and Updates on COMP360 Clinical Programs - Kalkine Media
Why is Compass Pathways stock rallying today? By Investing.com - Investing.com South Africa
Compass Pathways Q2 Earnings Call Highlights - Yahoo Finance
CMPS: Q2 2026 net loss widened to $253.8M; Phase 3 TRD milestones achieved; cash runway into 2028 - TradingView
Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78Volume Breadth - careplusvn.com
200,000 Shares in Compass Pathways PLC Sponsored ADR $CMPS Acquired by Vivo Capital LLC - MarketBeat
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78High Reward Trades - www.dars.gov.et
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78Ratio Spread Trade - dars.gov.et
Compass Pathways earnings on deck ahead of pivotal FDA filing - Investing.com
COMPASS Pathways (CMPS) Holds Steady Near Resistance Amid Modest GainsATR Trailing Stop - dars.gov.et
COMPASS Pathways (CMPS) Slips 3.73% as Stock Nears Key Support at $10.31Continuation Pattern Picks - careplusvn.com
1.20%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):